Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 September;51(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 September;51(3):244-50

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  ADVANCES IN PET - PART I 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 September;51(3):244-50

Copyright © 2007 EDIZIONI MINERVA MEDICA

language: English

Somatostatin receptor PET imaging with Gallium-68 labeled peptides

Win Z. 1, 2, Al-Nahhas A. 1, Rubello D. 3, Gross M. D. 4

1 Department of Nuclear Medicine Hammersmith Hospital, London, UK 2 Department of Radiology Hillingdon Hospital, Uxbridge, UK 3 Nuclear Medicine Service, PET Unit S. Maria della Misericordia Rovigo Hospital, Rovigo, Italy 4 Nuclear Medicine Department Department of Veteran Affairs Health System Ann Arbor, MI, USA


PDF


Imaging somatostatin receptor status with 68Ga labeled peptides has progressed rapidly over the last several years. It has generated great interest, and stimulated further research into the development of DOTA-derivative peptides. It has expanded our knowledge of receptor imaging and enhanced our appreciation of the difference between receptor-based and metabolic imaging, as well as more in-depth evaluation of tumor biology. The availability of the 68Ge/68Ga generator provides an attractive alternative to cyclotron-based positron-emitters, especially if kit-based radiopharmaceutical formulations based upon 68Ga are developed in the future.

top of page